Vistin Pharma ASALTS:0RAM 77 ROC (Joel Greenblatt) % is 40.88% as of Mar. 2026, which is 143% above its 10-year median of 16.79. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.61 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 978 Drug Manufacturers companies, Vistin Pharma ASA ranks better than 76.48% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Vistin Pharma ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 40.88%.
The historical rank and industry rank for Vistin Pharma ASA's ROC (Joel Greenblatt) % or its related term are showing as below:
LTS:0RAM'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -106.27 Med: 16.79 Max: 88.53
Current: 33.04
During the past 13 years, Vistin Pharma ASA's highest ROC (Joel Greenblatt) % was 88.53%. The lowest was -106.27%. And the median was 16.79%.
LTS:0RAM's ROC (Joel Greenblatt) % is ranked better than 76.48% of 978
companies
in the Drug Manufacturers industry
Industry Median: 11.45
vs LTS:0RAM: 33.04
Vistin Pharma ASA's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Vistin Pharma ASA ROC (Joel Greenblatt) % Related Terms
Vistin Pharma ASA ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 40.88% mean?
Vistin Pharma ASA (LTS:0RAM) has a ROC (Joel Greenblatt) % of 40.88% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vistin Pharma ASA and its competitors. This is 143% above median its historical median of 16.79. According to the industry distribution chart, Vistin Pharma ASA ranks #230 out of 978 companies in the Drug Manufacturers industry, placing it in the top 23.5%.
Is Vistin Pharma ASA's ROC (Joel Greenblatt) % too high?
Vistin Pharma ASA's current ROC (Joel Greenblatt) % of 40.88% is 143% above median its 10-year median of 16.79. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.45. Vistin Pharma ASA's value of 40.88% is 257% above this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #230 out of 978 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #230 out of 978 companies for ROC (Joel Greenblatt) %. This places Vistin Pharma ASA in the top 24% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.45. Vistin Pharma ASA's value of 40.88% is 257% above this benchmark. While the company's 10-year median is 16.79 vs. the industry median of 11.45, Vistin Pharma ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.45, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current ROC (Joel Greenblatt) % of 40.88% is 257% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current ROC (Joel Greenblatt) % is 40.88%, which is 143% above median its own 10-year median of 16.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current ROC (Joel Greenblatt) % is 40.88%, which is 143% above median its 10-year median of 16.79 and 257% above the Drug Manufacturers industry median of 11.45. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current ROC (Joel Greenblatt) % is 40.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.61.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
ROC (Joel Greenblatt) %: 40.88% (143% above median its 10-year median of 16.79)
GF Value™: kr25.61 vs. price of kr20.70 (19.2% below fair value)
Industry Position: 257% above the Drug Manufacturers median (#230 of 978)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for LTS:0RAM
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
